BioSpace News Archive

OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced that Daniel J. O’Connor, President and Chief Executive Officer of OncoSec, will present a company overview at the Ladenburg Thalmann 2019 Healthcare Conference on Tuesday, September 24, 2019, at 3:30 p.m. Eastern Time in New York, NY.

Reneo Pharmaceuticals, a clinical stage pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development has granted Orphan Drug Designation to the company’s lead drug candidate, REN001, for the treatment of fatty acid oxidation disorders (FAOD).

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and FibroGen, Inc. (Nasdaq: FGEN, Interim CEO: James A Schoeneck., “FibroGen”) today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) approved Evrenzo® (generic name: roxadustat) for the treatment of anemia associated with chronic kidney disease (CKD) in dialysis patients.

Astrotech Corporation (NASDAQ: ASTC) has created a new subsidiary company, Agriculture Technology Corporation (AG-TECH), in response to a growing number of inquiries from the agriculture industry requiring detection of trace levels of harmful pesticides in agricultural products

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Dupixent® (dupilumab) in a third indication.

Mallinckrodt Pharmaceuticals, a global biopharmaceutical company, will present at the Cantor Global Healthcare Conference at the InterContinental New York Barclay, 111 E. 48th St., New York on Wednesday, Oct. 2, 2019.

UnitedHealth Group (NYSE: UNH) will release its third quarter 2019 financial results on Tuesday, October 15, 2019, before the market opens, and will host a teleconference at 8:45 a.m. ET to discuss the results with analysts and investors

Harmony Biosciences, LLC (Harmony) announced today the recipients of the inaugural Patients at the Heart Grant, a competitive grant opportunity to fund innovative, patient-centric programs for the narcolepsy community.

Spinal Elements, a Carlsbad, CA-based spine technology company, today announced that the company will be introducing the Katana Lateral Access System at the North American Spine Society annual meeting in Chicago September 24th through September 27th.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today important new real-world evidence confirming XARELTO® (rivaroxaban) reduced the risk of recurrent venous thromboembolism (VTE) – or blood clots – in patients who are morbidly obese, with effectiveness and safety similar to warfarin.